Open Access Open Access  Restricted Access Subscription or Fee Access

A Research Study and Report on the Role of Clinical Pharmacy Services on the Management of Chronic Respiratory Disorder Asthma to an ESI Hospital

Rohit Chandrakant Kamble, Mekkanti Manasa Rekha, Rinku Mathappan


Chronic respiratory disorder (CRDs) are disease of the airways and other structure of the lung. A number of the foremost common are asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases and pulmonary hypertension. Additionally, to tobacco smoke, other risk factors including air pollution, occupational chemicals and dusts, and frequent lower respiratory infections during childhood. CRDs aren’t curable, however kinds of treatment that help dilate major air passages and improve shortness of breath can help control symptoms and increase the standard of life for people with the disease. Epidemiologically the burden of asthma in India is alarming with the median prevalence of 7%. As the symptoms of asthma ascend the severity ladder, the prediction on the rationale behind asthma is important from the treatment point of view. The goal of asthma treatment is to achieve good control of symptom, to cut back exacerbation and to boost quality of life, the burden of asthma is immense, with over 300 million individuals currently laid low with asthma worldwide, about a tenth of these living in India. Asthma causes limitations in daily activities, loss of school and work days, lung function impairment, and adverse socioeconomic burden. There are about 4 lakh deaths due to asthma annually and also the majority of deaths occur in low- and middleincome countries because of incorrect diagnosis, poor access to health care.


chronic respiratory disorder (CRDs), asthma, COPD, pulmonary hypertension, prevalence, socioeconomic.

Full Text:



Boulet LP. Pocket Guide for Asthma Management and Prevention.; 2019.

Salvi SS, Apte KK, Dhar R, et al. Asthma insights and management in India: Lessons learnt from the Asia Pacific - Asthma insights and management (AP-AIM) study. J Assoc Physicians India 2015; 63:36-43.

Koul PA, Patel D. Indian guidelines for asthma: Adherence is the key Indian guidelines for asthma: Adherence is the key Indian guidelines for asthma: Adherence is the key. Lung India 2019; 32(Supple 1):10-12. doi:10.4103/0970-2113.154511

Salvi SS. The burden of chronic respiratory diseases and their heterogeneity across the states of India:The Global Burden of Disease Study 1990 – 2016. Lancet 2018; 6: e478–89. doi:10.1016/S2214-109X (18)30409-1

NHLBI, national asthma education and prevention program, expert panel report 2. Guidelines for the diagnosis and management of asthma. NIH publication No. 97-4051. Bethesda, MD, US department of health and human services, 1997.

Campbell SC. Clinical aspects of inhaled anticholinergic therapy. Respiratory care 2000; 45:864-867.

Plotnick LH, Ducharme FM. Should inhaled anticholinergic be added to β2-agonist for treating acute childhood and adolescent asthma? A systematic review. Br Med J 1998; 317:971-977.

National institutes of health, national heart, lung, and blood institute. Global initiative for asthma (GINA). Global strategy for asthma management and prevention revised (2002). NHLBI/WHO workshop report. NIH publication No. 02-3659. Bethesda, MD, US department of health and human service, 2002.

Sorkness CA. cromolyn, nedocromil, leukotriene modifiers, and alternative anti-inflammatory agents in the treatment of paediatric asthma. In: murphy SA, Kelly HW, eds. Paediatric asthma. New York. Marcel Dekker, 1999:433-462.

Sorkness CA. leukotriene receptor antagonists in the treatment of asthma. Pharmacotherapy 2001; 21:34S-37S.

Price D. Tolerability of montelukast. Drugs 2000;59(supple 1):35-42.

Barsukiewics, Camille k; Raffle, Marshall w; RaffleNorma K (2010). The U.S health system: originsand function, sixth edition. Clifton Park, NY: can gage learning P .80. ISBN 978-1-4180-5298-0

American college of clinical pharmacy (June 2008). The definition of clinical pharmacy. Pharmacotherapy.28(6):816-7.

Greer N, Bolduc j, Geurkick E, Rector T, Olson K, Koeller E, MacDonald R, Wilt TJ (April 16). Pharmacist-; ed chronic disease management: A systematic review of effectiveness and harms compared with usual care. Annals of internal medicine.165(1):30-40.

Hoti k, Hughes J, Sunderland B (2011-04-30). An expanded prescribing role for pharmacists-An Australian perspective. The Australian medical journal.4(4):236-42

Collaborative drug therapy management (CDTM). Pharmacist’s letter / prescribers’ letter.25:250801.2009.


  • There are currently no refbacks.

Copyright (c) 2021 Research and Reviews: A Journal of Pharmaceutical Science